// App-Quantinova.ai

TMP34 2016 ASA : OnabotulinumtoxinA Treatment in Post-stroke Lower Limb Spasticity: Long-term Results From a Phase 3 Study

Researchers

Presenter

  • Alberto Esquenazi

Principal Investigators

  • Wolfgang H. Jost

  • Anthony Ward

  • Tinna Kwan

  • Grace Pan

  • Rozalina Dimitrova

Medical Centers

  • Staffordshire Univ, Stoke on Trent, United Kingdom

  • McGill, Montreal, QC, Canada

  • Univ of Freiburg, Freiburg, Baden-Wurttemberg, Germany

  • MossRehab Gait and Motion Analysis Lab, Elkins Park, PA

Locations

  • United States

  • Canada

  • United Kingdom

  • Germany

Companies

  • Allergan plc

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Stroke

Biomarkers

  • Gastrin

Drug/Treatment

  • OnabotulinumtoxinA

Outcome

  • N/A

Study Design

  • open label

  • double blind/blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved